中東およびアフリカの翼状片治療薬市場、疾患タイプ別（進行性翼状片および萎縮性翼状片）、ステージ別（ステージ2、ステージ3、ステージ1、ステージ4）、治療（人工涙液/局所潤滑剤およびステロイド点眼薬）、製剤別（点眼薬、眼軟膏、その他）、購入方法別（処方薬および市販薬（OTC））、人口タイプ別（高齢者および成人）、エンドユーザー別（病院、専門クリニック、在宅医療、その他）、流通チャネル別（小売薬局、病院薬局、オンライン薬局、その他） - 2029年までの業界動向および予測。
市場分析と洞察
翼状片は、眼瞼裂内の角膜縁結膜から始まり、角膜に進行する一般的な眼表面病変です。翼状片は、ギリシャ語で「翼」を意味する pterygos にちなんで名付けられました。この病変は、特徴的な翼のような外観を呈し、側頭よりも鼻縁によく発生します。紫外線への曝露は、翼状片の発生と強く関連しています。紫外線曝露の履歴が高い人や、赤道に近い地域に住んでいる人は、発生率が高くなります (屋外作業)。ある調査によると、男性は女性よりも発生率がやや高く、これは紫外線曝露率が高いためと考えられます。
目の充血、炎症、外観の変化を引き起こす可能性があります。乱視を引き起こし、視界がぼやける原因となる可能性があります。また、目の前面を覆う白っぽいまたはピンク色の腫瘍を引き起こす可能性があります。片目または両目に影響を及ぼす可能性があります。
翼状片は、全眼科検査中に顕微鏡を使用して眼の前部の構成部分を検査し、眼の白目の部分の角膜上の組織の成長の外観に基づいて診断されます。
Data Bridge Market Researchは、中東およびアフリカの翼状片治療薬市場は、2022年から2029年の予測期間中に3.5%のCAGRで成長すると分析しています。
|
レポートメトリック |
詳細 |
|
予測期間 |
2022年から2029年 |
|
基準年 |
2021 |
|
歴史的な年 |
2020 (2019-2014 にカスタマイズ可能) |
|
定量単位 |
売上高は百万米ドル、価格は米ドル |
|
対象セグメント |
疾患タイプ（進行性翼状片および萎縮性翼状片）、ステージ（ステージ 2、ステージ 3、ステージ 1、ステージ 4）、治療法（人工涙液/局所潤滑剤およびステロイド点眼薬）、製剤（点眼薬、眼軟膏、その他）、購入方法（処方薬および市販薬（OTC））、人口タイプ（高齢者および成人）、エンドユーザー（病院、専門クリニック、在宅医療、その他）、流通チャネル（小売薬局、病院薬局、オンライン薬局、その他） |
|
対象国 |
南アフリカ、サウジアラビア、UAE、エジプト、イスラエル、クウェート、その他の中東およびアフリカ |
|
対象となる市場プレーヤー |
ジョンソン・エンド・ジョンソン・サービス社（米国）、ノバルティス社（スイス）、アコーン・オペレーティング・カンパニー社（米国）、ボシュロム社（カナダ）、アッヴィ社（米国）、プレステージ・コンシューマー・ヘルスケア社（米国）、テア・ラボラトリーズ社（フランス）、ウェローナ・ファーマ社（インド）、バイエル社（ドイツ）、ザイダス・グループ、アムニール・ファーマシューティカルズ社（インド）、オアシス・メディカル社（米国）、アルコン社（スイス）、参天製薬株式会社（日本） |
市場の定義
翼状片は、眼瞼裂内の角膜縁結膜から始まり、角膜に進行する一般的な眼表面病変です。翼状片はギリシャ語の「翼」を意味する pterygos にちなんで名付けられました。この病変は、特徴的な翼のような外観を呈し、側頭よりも鼻縁によく発生します。紫外線への曝露は、翼状片の発生と強く関連しています。紫外線曝露の履歴が高い人や赤道に近い地域に住んでいる人は、発生率が高くなります (屋外作業)。ある調査によると、男性は女性よりも発生率がやや高いようですが、これは単に紫外線曝露率が高いためである可能性があります。
翼状片は、全眼科検査中に顕微鏡を使用して眼の前部の構成部分を検査し、眼の白目の部分の角膜上の組織の成長の外観に基づいて診断されます。
中東およびアフリカの翼状片治療薬市場の動向
このセクションでは、市場の推進要因、利点、機会、制約、課題について理解します。これらについては、以下で詳しく説明します。
ドライバー
- 眼科疾患の発生率と有病率の上昇
2021年に国立医学図書館（国立生物工学情報センター）に公開されたデータによると、有病率は場所によって異なる。赤道の北緯37度から南緯37度まで広がるキャメロンの「翼状片ベルト」で最も多く見られる。
翼状片の最も一般的な原因は、太陽からの紫外線（UV）への長期曝露（最も一般的な原因）と、暑く乾燥した天候、風、ほこりによる目の刺激です。肯定的な要因は、これが世界の翼状片治療薬市場の主な推進力であることを示しています。
- 高齢者人口の増加
世界中で高齢者人口が増加するにつれ、重度の眼痛を伴う眼科疾患の罹患率も増加しています。「視覚・眼科学研究協会」（ARVO）が発表した「2020年の世界失明率および遠方・近方視力障害：ビジョン2020の目標に向けた進捗状況と今後の展望」に掲載されたデータによると、失明者は推定4,190万人に上ります。
人口の増加に伴い、医療制度への圧力が高まっています。翼状片を含む眼科疾患の治療に対するケアとサービスの需要が高まっています。したがって、高齢人口の増加は中東およびアフリカの翼状片治療薬市場にとって大きなチャンスです。
機会
-
眼疾患の負担を軽減するためのプログラムと取り組み
失明予防のための国際機関は、眼疾患に対する認識を広め、その負担を軽減するために、評判の高いNGOや企業と共同でいくつかのプログラムや取り組みを立ち上げました。
例えば、
-
国際機関は、私たちのチルドレンズ・ビジョンと、ブライアン・ホールデン・ビジョン・インスティテュートとビジョン・フォー・ライフ基金（エシロールが創設）が共同で設立した失明予防のための取り組み（IAPB）を支持しています。
抑制/挑戦
さまざまな眼科疾患の罹患率が高まるにつれ、タイムリーな治療の必要性も高まっています。しかし、眼科疾患の治療と適切な投薬はそれほど安くはありません。最近の調査によると、局所ステロイドの価格は過去数年間で上昇しています。プレドニゾロンなどの一部の局所眼科ステロイドはやや安価ですが、その他の高度な薬剤や点眼薬は依然として高価です。
中東およびアフリカの翼状片治療薬市場レポートでは、最近の新しい開発、貿易規制、輸出入分析、生産分析、バリュー チェーンの最適化、市場シェア、国内および現地の市場プレーヤーの影響、新たな収益源の観点から見た機会の分析、市場規制の変更、戦略的市場成長分析、市場規模、カテゴリ市場の成長、アプリケーションのニッチと優位性、製品の承認、製品の発売、地理的拡大、市場における技術革新などの詳細が提供されます。翼状片治療薬市場に関する詳細情報を取得するには、アナリストの概要について Data Bridge Market Research にお問い合わせください。当社のチームは、市場の成長を達成するための情報に基づいた市場決定を行うお手伝いをします。
患者疫学分析
化学産業の拡大と世界的な汚染により、眼疾患の罹患率は急増し続けています。化学火傷や閃光火傷は、眼の表面の刺激により、重篤な眼痛を引き起こします。
2021年に国立医学図書館（国立生物工学情報センター）で公開されたデータによると、有病率は場所によって異なります。最も多く見られるのは、赤道の北緯37度から南緯37度まで広がるキャメロンの「翼状片ベルト」です。翼状片の有病率は、世界中で0.3～29％と報告されています。
Middle East and Africa pterygium drug market also provides detailed market analysis for patient analysis, prognosis, and cures. Prevalence, incidence, mortality, and adherence are some data variables available in the report. Direct or indirect impact analysis of epidemiology to the market growth are analyzed to create a more robust and cohot multivariate statistical model for forecasting the market in the growth period.
Post COVID-19 Impact on Middle East and Africa Pterygium Drug Market
COVID-19 has negatively affected the market. Lockdowns and isolations during pandemics complicate disease management and medication adherence. The lack of access to healthcare facilities for routine treatment and medication administration will further impact the market.
Recent Development
- In May 2022, Alcon announced the acquisition of EYSUVIS (loteprednol etabonate suspension) pharmaceutical eye drop from Kala Pharmaceuticals, Inc. The acquisition will complement the company's Systane family of eye drops, including preservative-free formulations.
Middle East and Africa Pterygium Drug Market Scope
Middle East and Africa pterygium drug market is categorized into eight notable segments based on disease type, stages, treatment, formulation, mode of purchase, population type, end-user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Disease Type
- Progressive Pterygium
- Atrophic Pterygium
Based on disease, the Middle East and Africa pterygium drug market is segmented into progressive pterygium and atrophic pterygium.
Stages
- Stage 1
- Stage 2
- Stage 3
- Stage 4
Based on stages, the Middle East and Africa pterygium drug market is segmented into stage 1, stage 2, stage 3, and stage 4.
Treatment
- Artificial Tears/Topical Lubricants
- Steroid Eye Drops
Based on treatment, the Middle East and Africa pterygium drug market is segmented into artificial tears/topical lubricants, and steroid eye drops.
Formulation
- Eye Drops
- Eye Ointments
- Others
Based on formulation, the Middle East and Africa pterygium drug market is segmented into eye drops, eye ointments, and others.
Mode of Purchase
- Prescription
- Over the Counter (OTC)
Based on mode of purchase, the Middle East and Africa pterygium drug market is segmented into prescription and over-the-counter (OTC).
Population Type
- Geriatric
- Adults
Based on population type, the Middle East and Africa pterygium drug market is segmented into geriatric and adults.
End-User
- Hospitals
- Specialty Clinics
- Home Healthcare
- Others
Based on end-user, the Middle East and Africa pterygium drug market is segmented into hospitals, specialty clinics, home healthcare, and others.
Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
- Others
Based on distribution channels, the Middle East and Africa pterygium drug market is segmented into retail pharmacies, hospital pharmacies, and online pharmacies.
Middle East and Africa Pterygium Drug Market Regional Analysis/Insights
Middle East and Africa pterygium drug market is analyzed, and market size insights and trends are provided by country, disease type, stages, treatment, formulation, mode of purchase, population type, end-user, and distribution channel. as referenced above.
The countries covered in the Middle East and Africa Middle East and Africa pterygium drug market report are South Africa, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait and Rest of Middle East and Africa.
Middle East and African pterygium drug market are expected to grow due to increased government initiatives to reduce the burden of eye illnesses.
South Africa is expected to dominate the Middle East and Africa pterygium drug market in terms of market share and market revenue. It will continue to flourish its dominance during the forecast period. This is due to the increasing awareness of early diagnosis and treatment of disease
The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of global brands and their challenges faced due to high competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Middle East and Africa Pterygium Drug Market Share Analysis
Middle East and Africa pterygium drug market competitive landscape provides details of the competitor. Details include company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, European presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the pterygium drug market.
Some of the major players operating in the Middle East and Africa pterygium drug market are Johnson & Johnson Services, Inc., Novartis AG, Akorn Operating Company LLC, Bausch & Lomb Incorporated, AbbVie Inc., Prestige Consumer Healthcare Inc., Théa Laboratories, Wellona Pharma, Bayer AG, Zydus Group, Amneal Pharmaceuticals LLC, OASIS Medical, Alcon, and Santen Pharmaceutical Co., Ltd. among others.
Research Methodology
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。市場データは、市場統計モデルとコヒーレント モデルを使用して分析および推定されます。さらに、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数の市場への影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。これとは別に、データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、企業市場シェア分析、測定基準、MEA 対地域、およびベンダー シェア分析が含まれます。さらに問い合わせる場合は、アナリストへの電話をリクエストしてください。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 CLASS SEGMENT LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL'S MODEL
4.2 PORTER'S 5 FORCES
4.3 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: NUMBER OF SURGERIES
5 EPIDEMIOLOGY
6 PIPELINE ANALYSIS
7 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: REGULATIONS
7.1 REGULATION IN THE U.S.
7.2 REGULATION IN EUROPE:
7.3 REGULATIONS IN CHINA:
7.4 REGULATIONS IN INDIA:
7.5 RELEVANT ACTS FOR THIS FRAMEWORK:
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 RISE IN INCIDENCES AND PREVALENCE OF OPHTHALMIC DISORDERS
8.1.2 RISE IN GERIATRIC POPULATION
8.1.3 INCREASE IN HEALTHCARE AWARENESS TO REDUCE THE RISK OF EYE ILLNESSES
8.2 RESTRAINTS
8.2.1 HIGH COST OF EYE TREATMENT AND MEDICATION
8.2.2 SIDE EFFECTS OF STEROIDS EYE DROPS
8.3 OPPORTUNITIES
8.3.1 PROGRAMS AND INITIATIVES TO REDUCE THE BURDEN OF EYE DISEASES
8.3.2 RISE IN HEALTHCARE EXPENDITURE AND DISPOSABLE INCOME
8.3.3 INCREASE IN RESEARCH AND DEVELOPMENT ACTIVITIES
8.4 CHALLENGES
8.4.1 STRINGENT RULES & REGULATIONS
8.4.2 EXPOSURE TO ULTRAVIOLET RADIATIONS
9 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET, BY DISEASE TYPE
9.1 OVERVIEW
9.2 PROGRESSIVE PTERYGIUM
9.3 ATROPHIC PTERYGIUM
10 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET, BY STAGES
10.1 OVERVIEW
10.2 STAGE 2
10.3 STAGE 3
10.4 STAGE 1
10.5 STAGE 4
11 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET, BY TREATMENT
11.1 OVERVIEW
11.2 ARTIFICIAL TEARS/TOPICAL LUBRICANTS
11.2.1 DEMULCENT
11.2.2 EMOLLIENTS
11.3 STEROID EYE DROPS
11.3.1 KETONE STEROIDS
11.3.1.1 PREDNOSOLONE
11.3.1.2 DEXAMETHASONE
11.3.1.3 FLUROMETHOLONE
11.3.1.4 OTHERS
11.3.2 ESTER STEROID (LOTERPREDNOL)
12 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET, BY FORMULATION
12.1 OVERVIEW
12.2 EYE DROPS
12.2.1 EYE DROPS WITH PRESERVATIVES
12.2.2 PRESERVATIVE-FREE EYE DROPS
12.3 EYE OINTMENTS
12.4 OTHERS
13 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE
13.1 OVERVIEW
13.2 PRESCRIPTION
13.3 OVER THE COUNTER (OTC)
14 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET, BY POPULATION TYPE
14.1 OVERVIEW
14.2 GERIATRIC
14.3 ADULTS
15 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 SPECIALTY CLINICS
15.4 HOME HEALTHCARE
15.5 OTHERS
16 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 RETAIL PHARMACIES
16.3 HOSPITAL PHARMACIES
16.4 ONLINE PHARMACIES
16.5 OTHERS
17 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET, BY REGION
17.1 MIDDLE EAST AND AFRICA
17.1.1 SOUTH AFRICA
17.1.2 EGYPT
17.1.3 ISRAEL
17.1.4 UAE
17.1.5 SAUDI ARABIA
17.1.6 KUWAIT
17.1.7 REST OF MIDDLE EAST AND AFRICA
18 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
19 SWOT ANALYSIS
20 COMPANY PROFILES
20.1 ALCON
20.1.1 COMPANY SNAPSHOT
20.1.2 RECENT FINANCIALS
20.1.3 COMPANY SHARE ANALYSIS
20.1.4 PRODUCT PORTFOLIO
20.1.5 RECENT DEVELOPMENTS
20.2 ABBVIE INC.
20.2.1 COMPANY SNAPSHOT
20.2.2 REVENUE ANALYSIS
20.2.3 COMPANY SHARE ANALYSIS
20.2.4 PRODUCT PORTFOLIO
20.2.5 RECENT DEVELOPMENT
20.3 BAUSCH & LOMB INCORPORATED
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 COMPANY SHARE ANALYSIS
20.3.4 PRODUCT PORTFOLIO
20.3.5 RECENT DEVELOPMENT
20.4 JOHNSON & JOHNSON SERVICES, INC.
20.4.1 COMPANY SNAPSHOT
20.4.2 REVENUE ANALYSIS
20.4.3 COMPANY SHARE ANALYSIS
20.4.4 PRODUCT PORTFOLIO
20.4.5 RECENT DEVELOPMENTS
20.5 BAYER AG
20.5.1 COMPANY SNAPSHOT
20.5.2 REVENUE ANALYSIS
20.5.3 COMPANY SHARE ANALYSIS
20.5.4 PRODUCT PORTFOLIO
20.5.5 RECENT DEVELOPMENTS
20.6 NOVARTIS AG
20.6.1 COMPANY SNAPSHOT
20.6.2 REVENUE ANALYSIS
20.6.3 PRODUCT PORTFOLIO
20.6.4 RECENT DEVELOPMENTS
20.7 SANTEN PHARMACEUTICAL CO., LTD.
20.7.1 COMPANY SNAPSHOT
20.7.2 RECENT FINANCIALS
20.7.3 PRODUCT PORTFOLIO
20.7.4 RECENT DEVELOPMENT
20.8 AKORN OPERATING COMPANY LLC
20.8.1 COMPANY SNAPSHOT
20.8.2 PRODUCT PORTFOLIO
20.8.3 RECENT DEVELOPMENT
20.9 AMNEAL PHARMACEUTICALS LLC.
20.9.1 COMPANY SNAPSHOT
20.9.2 REVENUE ANALYSIS
20.9.3 PRODUCT PORTFOLIO
20.9.4 RECENT DEVELOPMENTS
20.1 EYERIS VISIONCARE PVT. LTD.
20.10.1 COMPANY SNAPSHOT
20.10.2 PRODUCT PORTFOLIO
20.10.3 RECENT DEVELOPMENTS
20.11 MAYA BIOTECH PRIVATE LIMITED
20.11.1 COMPANY SNAPSHOT
20.11.2 PRODUCT PORTFOLIO
20.11.3 RECENT DEVELOPMENTS
20.12 OASIS MEDICAL
20.12.1 COMPANY SNAPSHOT
20.12.2 PRODUCT PORTFOLIO
20.12.3 RECENT DEVELOPMENTS
20.13 PRESTIGE CONSUMER HEALTHCARE INC.
20.13.1 COMPANY SNAPSHOT
20.13.2 REVENUE ANALYSIS
20.13.3 PRODUCT PORTFOLIO
20.13.4 RECENT DEVELOPMENT
20.14 SAGER PHARMA
20.14.1 COMPANY SNAPSHOT
20.14.2 PRODUCT PORTFOLIO
20.14.3 RECENT DEVELOPMENTS
20.15 SIMILASAN CORPORATION
20.15.1 COMPANY SNAPSHOT
20.15.2 PRODUCT PORTFOLIO
20.15.3 RECENT DEVELOPMENTS
20.16 SPECTRA VISION CARE
20.16.1 COMPANY SNAPSHOT
20.16.2 PRODUCT PORTFOLIO
20.16.3 RECENT DEVELOPMENTS
20.17 SYLENTIS
20.17.1 COMPANY SNAPSHOT
20.17.2 PRODUCT PORTFOLIO
20.17.3 RECENT DEVELOPMENT
20.18 THÉA LABORATORIES
20.18.1 COMPANY SNAPSHOT
20.18.2 PRODUCT PORTFOLIO
20.18.3 RECENT DEVELOPMENTS
20.19 WELLONA PHARMA
20.19.1 COMPANY SNAPSHOT
20.19.2 PRODUCT PORTFOLIO
20.19.3 RECENT DEVELOPMENTS
20.2 ZYDUS GROUP
20.20.1 COMPANY SNAPSHOT
20.20.2 REVENUE ANALYSIS
20.20.3 PRODUCT PORTFOLIO
20.20.4 RECENT DEVELOPMENTS
21 QUESTIONNAIRE
22 RELATED REPORTS
表のリスト
TABLE 1 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET, PIPELINE ANALYSIS
TABLE 2 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 3 MIDDLE EAST & AFRICA PROGRESSIVE PTERYGIUM IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 MIDDLE EAST & AFRICA ATROPHIC PTERYGIUM IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET , BY STAGES, 2020-2029 (USD MILLION)
TABLE 6 MIDDLE EAST & AFRICA STAGE 2 IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 MIDDLE EAST & AFRICA STAGE 3 IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 MIDDLE EAST & AFRICA STAGE 1 IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 9 MIDDLE EAST & AFRICA STAGE 4 IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 11 MIDDLE EAST & AFRICA ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA STEROID EYE DROPS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA STEROID EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA EYE DROPS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA EYE OINTMENTS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA OTHERS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA PRESCRIPTION IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA OVER THE COUNTER (OTC) IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 25 MIDDLE EAST & AFRICA GERIATRICS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA ADULTS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 28 MIDDLE EAST & AFRICA HOSPITALS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 MIDDLE EAST & AFRICA SPECIALTY CLINICS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 MIDDLE EAST & AFRICA HOME HEALTHCARE IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA OTHERS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA RETAIL PHARMACIES IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 MIDDLE EAST & AFRICA HOSPITAL PHARMACIES IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 MIDDLE EAST & AFRICA ONLINE PHARMACIES IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 MIDDLE EAST & AFRICA OTHERS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA PTERYGIUM DRUG MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 47 MIDDLE EAST AND AFRICA PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 49 MIDDLE EAST AND AFRICA PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 50 SOUTH AFRICA PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 51 SOUTH AFRICA PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 52 SOUTH AFRICA PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 53 SOUTH AFRICA ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 54 SOUTH AFRICA STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 55 SOUTH AFRICA KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 56 SOUTH AFRICA PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 57 SOUTH AFRICA EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 58 SOUTH AFRICA PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 59 SOUTH AFRICA PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 60 SOUTH AFRICA PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 61 SOUTH AFRICA PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 62 EGYPT PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 63 EGYPT PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 64 EGYPT PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 65 EGYPT ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 66 EGYPT STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 67 EGYPT KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 68 EGYPT PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 69 EGYPT EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 70 EGYPT PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 71 EGYPT PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 72 EGYPT PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 73 EGYPT PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 74 ISRAEL PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 75 ISRAEL PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 76 ISRAEL PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 77 ISRAEL ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 78 ISRAEL STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 79 ISRAEL KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 80 ISRAEL PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 81 ISRAEL EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 82 ISRAEL PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 83 ISRAEL PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 84 ISRAEL PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 85 ISRAEL PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 86 UAE PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 87 UAE PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 88 UAE PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 89 UAE ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 90 UAE STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 91 UAE KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 92 UAE PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 93 UAE EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 94 UAE PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 95 UAE PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 96 UAE PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 97 UAE PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 98 SAUDI ARABIA PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 99 SAUDI ARABIA PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 100 SAUDI ARABIA PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 101 SAUDI ARABIA ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 102 SAUDI ARABIA STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 103 SAUDI ARABIA KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 104 SAUDI ARABIA PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 105 SAUDI ARABIA EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 106 SAUDI ARABIA PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 107 SAUDI ARABIA PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 108 SAUDI ARABIA PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 109 SAUDI ARABIA PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 110 KUWAIT PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 111 KUWAIT PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 112 KUWAIT PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 113 KUWAIT ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 114 KUWAIT STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 115 KUWAIT KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 116 KUWAIT PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 117 KUWAIT EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 118 KUWAIT PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 119 KUWAIT PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 120 KUWAIT PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 121 KUWAIT PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 122 REST OF MIDDLE EAST AND AFRICA PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
図表一覧
FIGURE 1 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: DBMR POSITION GRID
FIGURE 8 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: END USER COVERAGE GRID
FIGURE 10 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: SEGMENTATION
FIGURE 11 ASIA-PACIFIC IS ANTICIPATED TO DOMINATE THE PTERYGIUM DRUG MARKET AND GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 INCREASING PREVALENCE OF OPHTHALMIC DISORDERS AND RISE IN GERIATRIC POPULATION ARE EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET FROM 2022 TO 2029
FIGURE 13 PROGRESSIVE PTERYGIUM SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET FROM 2022 & 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET
FIGURE 15 AGEING POPULATION IN THE WORLD (IN MILLIONS)
FIGURE 16 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY DISEASE TYPE, 2021
FIGURE 17 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY DISEASE TYPE, 2022-2029 (USD MILLION)
FIGURE 18 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY DISEASE TYPE, CAGR (2022-2029)
FIGURE 19 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 20 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY STAGES, 2021
FIGURE 21 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY STAGES, 2022-2029 (USD MILLION)
FIGURE 22 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY STAGES, CAGR (2022-2029)
FIGURE 23 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY STAGES, LIFELINE CURVE
FIGURE 24 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY TREATMENT, 2021
FIGURE 25 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY TREATMENT, 2022-2029 (USD MILLION)
FIGURE 26 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY TREATMENT, CAGR (2022-2029)
FIGURE 27 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 28 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY FORMULATION, 2021
FIGURE 29 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY FORMULATION, 2022-2029 (USD MILLION)
FIGURE 30 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY FORMULATION, CAGR (2022-2029)
FIGURE 31 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY FORMULATION, LIFELINE CURVE
FIGURE 32 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY MODE OF PURCHASE, 2021
FIGURE 33 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY MODE OF PURCHASE, 2022-2029 (USD MILLION)
FIGURE 34 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY MODE OF PURCHASE, CAGR (2022-2029)
FIGURE 35 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY MODE OF PURCHASE, LIFELINE CURVE
FIGURE 36 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY POPULATION TYPE, 2021
FIGURE 37 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY POPULATION TYPE, 2022-2029 (USD MILLION)
FIGURE 38 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY POPULATION TYPE, CAGR (2022-2029)
FIGURE 39 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 40 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY END USER, 2021
FIGURE 41 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 42 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY END USER, CAGR (2022-2029)
FIGURE 43 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY END USER, LIFELINE CURVE
FIGURE 44 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 45 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 46 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 47 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 48 MIDDLE EAST AND AFRICA PTERYGIUM DRUG MARKET: SNAPSHOT (2021)
FIGURE 49 MIDDLE EAST AND AFRICA PTERYGIUM DRUG MARKET: BY COUNTRY (2021)
FIGURE 50 MIDDLE EAST AND AFRICA PTERYGIUM DRUG MARKET: BY COUNTRY (2022 & 2029)
FIGURE 51 MIDDLE EAST AND AFRICA PTERYGIUM DRUG MARKET: BY COUNTRY (2021 & 2029)
FIGURE 52 MIDDLE EAST AND AFRICA PTERYGIUM DRUG MARKET: BY DISEASE TYPE (2022-2029)
FIGURE 53 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: COMPANY SHARE 2021 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
